Abstract Treatment of lung cancer remains a challenge, and lung cancer is still the leading
cause of cancer‐related mortality. Immunotherapy has previously failed in lung cancer but …

Oncolytic viruses selectively target and kill cancer cells in an immunogenic fashion, thus
supporting the establishment of therapeutically relevant tumor-specific immune responses …

Immune checkpoint blockers (ICBs) are literally revolutionizing the clinical management of
an ever more diversified panel of oncological indications. Although considerable attention …

Simple Summary Cancer is one of the leading causes of mortality around the globe. In the
past decades, there has been rapid progress in the development of tools to detect, screen …

Background The high postoperative recurrence rate and refractoriness of relapsed tumors
are still a conundrum for the clinical management of osteosarcoma (OS). New therapeutic …

Harnessing the broad immunostimulatory capabilities of chemotherapy in combination with
immune checkpoint inhibitors has improved immunotherapy outcomes in patients with …

The three major conventional treatments: surgery, chemotherapy, and radiation therapy,
have been commonly performed for lung cancer. However, lung cancer is still the leading …

The goal of cancer immunotherapy is to establish new or boost pre-existing anticancer
immune responses that eradicate malignant cells while generating immunological memory …

With a 5-year survival rate of just 8%, pancreatic cancer (PC) is projected to be the second
leading cause of cancer deaths by 2030. Most PC patients are not eligible for surgery with …

Advanced, late-stage Epstein-Barr virus (EBV)-positive nasopharyngeal carcinoma (NPC) is
incurable, and its treatment remains a clinical and therapeutic challenge. Results from a …